Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00532519
First received: September 19, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.


Condition Intervention
Prurigo Nodularis
Drug: citalopram (cipralex)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Intervention Details:
    Drug: citalopram (cipralex)
    10-20 mg/day, for 12 weeks.
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

Exclusion Criteria:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532519

Contacts
Contact: Liran Horev, MD OO97226777111 LIRAN_CH@BEZEQINT.NET

Locations
Israel
: Hadassah Medical Organization, Not yet recruiting
Jerusalem, Israel
Contact: Arik Tzukert, DMD    00 972 2 6776095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    00 972 2 6777572    : lhadas@hadassah.org.il   
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: liran horev, md Hadassah Medical Organization
Principal Investigator: rena cooper-kazaz, md Hadassah Medical Organization
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00532519     History of Changes
Other Study ID Numbers: horcoop-hmo-ctil
Study First Received: September 19, 2007
Last Updated: September 19, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Prurigo
Neurodermatitis
Skin Diseases
Dermatitis
Skin Diseases, Eczematous
Citalopram
Serotonin Uptake Inhibitors
Dexetimide
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents

ClinicalTrials.gov processed this record on April 17, 2014